

Section 1.	antifying Inform	antia m			
Id	entifying Inform	nation			
1. Given Name (First Na Victor	ame)	2. Surname (Last Name) Gura		3. Date 04-April-2016	
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Aut		
5. Manuscript Title A Wearable Artificial Kidney for Patients with End-Stage Renal Dise		isease		_	
6. Manuscript Identifyi 86397-INS-CMED-1	ng Number (if you kn	now it)			
Section 2. Th	e Work Under Co	onsideration for Publ	ication		
	itted work (including ?	but not limited to grants, o		ment, commercial, private foundation, etc.) study design, manuscript preparation,	for
•	he appropriate info	ormation below. If you ha	ave more than one er	ntity press the "ADD" button to add a ro	w.
Name of Institution/	Company	Grant	on-Financial Other Support?	.? Comments	
Blood Purification Techno	logies Inc.		✓		
Section 3. Re	levant financial	activities outside the	submitted work.		
of compensation) wit	th entities as descri	ibed in the instructions. l	Jse one line for each	ncial relationships (regardless of amour entity; add as many lines as you need b the 36 months prior to publication.	
Are there any relevar					
If yes, please fill out t	he appropriate info	ormation below.			
Name of Entity		Grant	on-Financial Other	? Comments	
Blood Purification Techno	logies Inc.			Stock holder	

Gura 2



Section 4.	Intellectual	Property	Patents	& Copyri	ghts			
•	out the appropr	iate informa	tion belov	w. If you ha	•		✓ Yes No s the "ADD" button to	add a row.
Paten	nt?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments	
6,960179-7597677-7 3-7854718	7645253-730932		✓					
Section 5.	Relationshi	ps not cove	ered abo	ve				
potentially influe Yes, the follo No other rela	encing, what yo wing relationsh ationships/cond anuscript accep	u wrote in th iips/condition itions/circum otance, journa uthors to disa	e submitt ns/circum nstances t als will asl	ted work? Instances are that presen	e present (ex t a potential o confirm and	plain below): conflict of intere	odate their disclosure	
Based on the about the below.	ove disclosures,	this form wi	ll automa	tically gene	erate a disclo	sure statement, v	vhich will appear in th	ie box
	ood Purificatior 577-77645253-7	Technologie 309323-7854	es Inc. out 718-7896	tside the su 5829-78287	bmitted woi 61- 7892196	rk; in addition, D	onduct of the study; or. Gura reports patent	

Gura 3



Section 1.	Identifying Inform	nation					
1. Given Name (Fi Matthew	rst Name)	2. Surname (Last Name) Rivara	3. Date 30-March-2016				
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Author's Name Jonathan Himmelfarb				
5. Manuscript Title A Wearable Artificial Kidney for Patients with End-Stage Ren		s with End-Stage Renal Dis	ease				
6. Manuscript Ider 86397-INS-CMED	ntifying Number (if you kr)-1	now it)					
Section 2.	The Work Under C	onsideration for Public	ation				
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,				
Section 3.	Relevant financial	activities outside the s	ubmitted work.				
of compensation clicking the "Ado) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .				
Section 4.	Intellectual Proper	rty Patents & Copyric	jhts				
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No				

Rivara 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Rivara has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Rivara 3



Section 1.	Identifying Inform	nation					
1. Given Name (Fi	rst Name)	2. Surname (Last Name) Bieber	3. Date 30-March-2016				
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Author's Name Jonathan Himmelfarb				
5. Manuscript Title A Wearable Artif		s with End-Stage Renal Dis	ease				
6. Manuscript Ider 86397-INS-CMEE	ntifying Number (if you kr D-1	now it)					
Section 2.	The Work Under Co	onsideration for Public	ation				
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,				
Section 3.	Relevant financial	activities outside the s	ubmitted work.				
of compensation clicking the "Ado) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .				
Section 4.	Intellectual Proper	rty Patents & Copyric	jhts				
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No				

Bieber 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Bieber has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Bieber 3



Section 1.	Identifying Inform	nation					
1. Given Name (Fii Raj	rst Name)	2. Surname (Last Name) Munshi	3. Date 29-March-2016				
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Author's Name Jonathan Himmelfarb				
5. Manuscript Title A Wearable Artificial Kidney for Patients with End-Stage Renal I		s with End-Stage Renal Dis	ease				
6. Manuscript Ider 86397-INS-CMED	ntifying Number (if you kr D-1	now it)					
Section 2.	The Work Under Co	onsideration for Public	ation				
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,				
Section 3.	Relevant financial	activities outside the s	ubmitted work.				
of compensation clicking the "Add) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .				
Section 4.	Intellectual Prope	rty Patents & Copyric	jhts				
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No				

Munshi 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Munshi has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Munshi 3



Section 1. Identifying Inform	nation		
Given Name (First Name) Nancy Colobong	2. Surname (Last Name) Smith	3. Date 29-March-2016	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Jonathan Himmelfarb	
5. Manuscript Title A Wearable Artificial Kidney for Patients with End-Stage Renal Disease			
6. Manuscript Identifying Number (if you kr 86397-INS-CMED-1	now it)	_	
Section 2. The Work Under C	onsideration for Public	ation	
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,	
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr	in the table to indicate who ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .	
Section 4. Intellectual Proper	rty Patents & Copyrig	ihts	
Do you have any patents, whether plan			

Smith 2



Section 5.					
Section 5.	Relationships not covered above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?					
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):				
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest				
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.					
Section 6.	Disclosure Statement				
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box				
ARNP Smith has	nothing to disclose.				

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Smith 3



Section 1.	Identifying Inform	nation					
1. Given Name (Fi	rst Name)	2. Surname (Last Name) Linke	3. Date 29-March-2016				
4. Are you the corresponding author?		Yes ✓ No	Corresponding Author's Name Jonathan Himmelfarb				
5. Manuscript Title A Wearable Artificial Kidney for Patients with End-Stage Renal Di		s with End-Stage Renal Dis	ease				
6. Manuscript Ider 86397-INS-CMED	ntifying Number (if you kr)-1	now it)					
Section 2.	The Work Under Co	onsideration for Public	ation				
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,				
Section 3.	Relevant financial	activities outside the s	ubmitted work.				
of compensation clicking the "Ado) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .				
Section 4.	Intellectual Proper	rty Patents & Copyric	jhts				
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No				

Linke 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Lori Linke has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Linke 3



Section 1.	Identifying Inform	nation	
1. Given Name (Fii John	rst Name)	2. Surname (Last Name) Kundzins	3. Date 30-March-2016
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Dr. Jonathan Himmelfarb
5. Manuscript Title A Wearable Artif		s with End-Stage Renal Dis	ease
6. Manuscript Ider 86397-INS-CMED	ntifying Number (if you kr)-1	now it)	
			_
Section 2.	The Work Under Co	onsideration for Public	ation
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	ubmitted work.
of compensation clicking the "Add) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .
Section 4.	Intellectual Proper	rty Patents & Copyric	jhts
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Kundzins 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Mr. Kundzins ha	s nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Kundzins 3



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Masoud	2. Surname (Last Name) Beizai	3. Date 29-March-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Dr. Jonathan Himmelfarb
5. Manuscript Title A Wearable Artificial Kidney for Patients	with End-Stage Renal Dis	ease
6. Manuscript Identifying Number (if you kn 86397-INS-CMED-1	now it)	
Section 2. The Work Under Co	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
If yes, please fill out the appropriate info		ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Non Fees? S	n-Financial other? Comments
Blood Purification Technologies, Inc.		
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflicts of intere	est? Yes ✓ No	
Section 4. Intellectual Proper	ty Patents & Copyric	ghts
Do you have any patents, whether plant	· =	• — —
If yes, please fill out the appropriate info Excess rows can be removed by pressing		ve more than one entity press the "ADD" button to add a row.

Beizai 2



Patent?	Pending?	Issued?	Licensed?	Royalties ?	Licensee?	Comments	
US 8034161 B2		V					
		_	_	_			
Section 5. Relationshi	ips not cove	ered abo	ove				
Are there other relationships or potentially influencing, what yo			-	eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh	nips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/cond	litions/circum	nstances	that presen	t a potential	conflict of interes	st	
At the time of manuscript accep On occasion, journals may ask a							nents.
Section 6. Disclosure S	Statement						
Based on the above disclosures, below.	, this form wi	ll automa	atically gene	erate a disclo	sure statement, v	which will appear in the box	
Dr. Beizai reports personal fees Beizai has a patent US 8034161		Purificatio	on Technolo	ogies, Inc. du	iring the conduct	of the study. In addition, D	r.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Beizai 3



Section 1. Identifying Inform	aation	
1. Given Name (First Name) Carlos	2. Surname (Last Name) Ezon	3. Date 30-March-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Jonathan Himmelfarb
5. Manuscript Title A Wearable Artificial Kidney for Patients	with End-Stage Renal Dis	ease
6. Manuscript Identifying Number (if you kr 86397-INS-CMED-1	now it)	_
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation, we more than one entity press the "ADD" button to add a row.
Excess rows can be removed by pressing	g the "X" button.	
Name of Institution/Company	Grant	n-Financial other? Comments
Blood Purification Technologies, Inc.		
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Use port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Proper	ty Patents & Copyric	ghts
Do you have any patents, whether plant If yes, please fill out the appropriate info Excess rows can be removed by pressing	ormation below. If you hav	roadly relevant to the work? Yes No Ye more than one entity press the "ADD" button to add a row.

Ezon 2



Patent?	Pending?	Issued?	Licensed ?	Royalties?	Licensee ?	Comments	
US 8034161 B2		✓					
Section 5. Relationsh	ips not cov	ered abo	ove				
Are there other relationships o potentially influencing, what y				eive to have	influenced, or tha	at give the appearance of	
Yes, the following relations	hips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/con	ditions/circun	nstances	that presen	t a potential	conflict of interes	st	
At the time of manuscript acce On occasion, journals may ask							ients.
Section 6. Disclosure	Statement						
Based on the above disclosured below.	s, this form wi	ll automa	atically gene	erate a disclo	sure statement, v	vhich will appear in the box	
Dr. Ezon reports personal fees Ezon has a patent US 8034161		urification	n Technolog	gies, Inc. duri	ng the conduct o	f the study. In addition, Dr.	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Ezon 3



Section 1.	Identifying Inform	nation	
1. Given Name (Fi Larry	, ,	2. Surname (Last Name) Kessler	3. Date 05-April-2016
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Jonathan Himmelfarb
5. Manuscript Title A Wearable Artif		s with End-Stage Renal Dis	ease
6. Manuscript Ide	ntifying Number (if you kr D-1	now it)	
			_
Section 2.	The Work Under C	onsideration for Public	cation
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Continue 2			
Section 3.	Relevant financial	activities outside the s	ubmitted work.
of compensation clicking the "Add	n) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4.	Intellectual Prope	rty Patents & Copyric	ghts
Do you have any	patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes V No

Kessler 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Kessler has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Kessler 3



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Jonathan	2. Surname (Last Name) Himmelfarb	3. Date 29-March-2016
4. Are you the corresponding author?	✓ Yes No	
5. Manuscript Title A Wearable Artificial Kidney for Patient	s with End-Stage Renal Disease	
6. Manuscript Identifying Number (if you k 86397-INS-CMED-1	now it)	
Section 2. The Work Under C	onsideration for Publication	
	eive payment or services from a third party (government, c g but not limited to grants, data monitoring board, study c est? Yes V No	
Section 3. Relevant financial	activities outside the submitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr	in the table to indicate whether you have financial re ibed in the instructions. Use one line for each entity; port relationships that were present during the 36	add as many lines as you need by
Section 4. Intellectual Prope	rty Patents & Copyrights	
Do you have any patents, whether plan	ned, pending or issued, broadly relevant to the work	</td

Himmelfarb 2



Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	itionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Himmelfarb	has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Himmelfarb 3

TREND Statement Checklist

Paper Section/	Item No	Descriptor	Repo	
Topic		The state of the s	$\nabla \Box$	Pg#
Title and Abst	ract			
Title and Abst	1	Information on how unit were allocated to interventions	V	2
Abstract	_	Structured abstract recommended	1	2
		Information on target population or study sample	V	2
Introduction				
Background	2	Scientific background and explanation of rationale	V	4
		Theories used in designing behavioral interventions	NA	
Methods				
Participants	3	 Eligibility criteria for participants, including criteria at different levels in recruitment/sampling plan (e.g., cities, clinics, subjects) 	√	1フ
		Method of recruitment (e.g., referral, self-selection), including the sampling method if a systematic sampling plan was implemented	✓	17
	**	Recruitment setting	\checkmark	17
		Settings and locations where the data were collected	V	17
Interventions	4	Details of the interventions intended for each study condition and how		
		and when they were actually administered, specifically including:	\vee	
		Content: what was given?	√	18
		o Delivery method: how was the content given?	✓	18
		 Unit of delivery: how were the subjects grouped during delivery? 	NA	
		Deliverer: who delivered the intervention?	√	17
		 Setting: where was the intervention delivered? 	√	17
		 Exposure quantity and duration: how many sessions or episodes or 		17
	1	events were intended to be delivered? How long were they	\checkmark	!
		intended to last?	ļ	19
		o Time span: how long was it intended to take to deliver the	/	15
		intervention to each unit?	1 16	1 /
		Activities to increase compliance or adherence (e.g., incentives)	NA	
Objectives	5	Specific objectives and hypotheses	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	5
Outcomes	6	Clearly defined primary and secondary outcome measures	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	5
		Methods used to collect data and any methods used to enhance the	$ \sqrt{} $	19-
		quality of measurements		20
		Information on validated instruments such as psychometric and biometric	√ .	20
		properties		-
Sample Size	7	How sample size was determined and, when applicable, explanation of any	$ \sqrt{} $	8
	 _	interim analyses and stopping rules		
Assignment	8	Unit of assignment (the unit being assigned to study condition, e.g., individual group community)	NA	_
Method		individual, group, community)	kt /	
		Method used to assign units to study conditions, including details of any restriction (a.g. blocking stratification minimization)	NA	
		restriction (e.g., blocking, stratification, minimization)	10	
		Inclusion of aspects employed to help minimize potential bias induced due to non rendemination (e.g., matching)	M/A	
		to non-randomization (e.g., matching)	1	L

TREND Statement Checklist

Blinding (masking)	9	 Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed. 	N/A	
Unit of Analysis	10	 Description of the smallest unit that is being analyzed to assess intervention effects (e.g., individual, group, or community) 	√	20 ⁻ 21
		 If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis) 	V/A	-
Statistical Methods	11	Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data	1	19-20
		Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis	NA	
		Methods for imputing missing data, if used	NJA	<u>-</u>
		Statistical software or programs used	V	22
Results				
Participant flow	12	Flow of participants through each stage of the study: enrollment, assignment, allocation, and intervention exposure, follow-up, analysis (a diagram is strongly recommended)	1	32
		Enrollment: the numbers of participants screened for eligibility, found to be eligible or not eligible, declined to be enrolled, and enrolled in the study	1	32
		 Assignment: the numbers of participants assigned to a study condition 	1	32,
		 Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention 	1	32
		 Follow-up: the number of participants who completed the follow-up or did not complete the follow-up (i.e., lost to follow-up), by study condition 	1	32
		 Analysis: the number of participants included in or excluded from the main analysis, by study condition 	1	32
		Description of protocol deviations from study as planned, along with reasons	√	8
Recruitment	13	Dates defining the periods of recruitment and follow-up	√	17
Baseline Data	14	Baseline demographic and clinical characteristics of participants in each study condition	√	29
		Baseline characteristics for each study condition relevant to specific disease prevention research	N/A	_
		Baseline comparisons of those lost to follow-up and those retained, overall and by study condition	N/A	_
		Comparison between study population at baseline and target population	NA	-
Baseline	15	 of interest Data on study group equivalence at baseline and statistical methods used 	<u> </u>	

TREND Statement Checklist

Numbers analyzed	16	 Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible 	1	32
		 Indication of whether the analysis strategy was "intention to treat" or, if not, description of how non-compliers were treated in the analyses 	\checkmark	32,
Outcomes and estimation	17	 For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision 	NA	_
		Inclusion of null and negative findings	V	8-0
		 Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any 	N/A	
Ancillary analyses	18	 Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory 	NA	
Adverse events	19	 Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals) 	1	8-9
DISCUSSION				
Interpretation	20	Interpretation of the results, taking into account study hypotheses,	1	10-
		sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study	ľ	16
		· · · · · · · · · · · · · · · · · · ·	√ √	1
		 and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative 	√ √	10-
		 and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations Discussion of the success of and barriers to implementing the intervention, 		10-
Generalizability	21	 and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations Discussion of the success of and barriers to implementing the intervention, fidelity of implementation 		16 10 10 14 15

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. American Journal of Public Health, 94, 361-366. For more information, visit: http://www.cdc.gov/trendstatement/